Non-Invasive Continuous Blood Pressure Monitoring Using the ClearSight System for Pregnant Women at High Risk of Postpartum Hemorrhage

Postpartum hemorrhage (PPH) remains one of the leading causes of maternal morbidity and mortality worldwide. Early detection and effective management of hemodynamic changes during labor and delivery are critical in improving outcomes for women at high risk of PPH. Continuous arterial pressure monitoring plays a vital role in this process; however, traditional invasive methods come with risks and discomfort. The ClearSight system, a non-invasive continuous blood pressure monitoring technology, is emerging as a valuable tool in obstetric care, particularly for pregnant women at elevated risk of postpartum hemorrhage.

Understanding Postpartum Hemorrhage and Its Risks

Postpartum hemorrhage is generally defined as blood loss exceeding 500 mL after vaginal delivery or greater than 1000 mL following cesarean section. It can result from uterine atony, trauma, retained placental tissue, or coagulopathy, and requires rapid identification and intervention.

Women at high risk of PPH include those with:

• History of prior PPH
• Multiple pregnancies or polyhydramnios
• Pre-eclampsia or hypertensive disorders of pregnancy
• Placenta previa or accreta
• Prolonged labor or use of labor-inducing drugs
• Coagulation disorders

Monitoring blood pressure and hemodynamic status is essential because hypotension may signal significant blood loss before clinical symptoms become apparent. Continuous monitoring allows clinicians to detect subtle changes early and respond promptly.

Limitations of Traditional Blood Pressure Monitoring in Obstetrics

Standard blood pressure monitoring techniques in labor and delivery typically include intermittent measurements using a manual or automatic cuff. While this method is widely used, it has limitations:

• Intermittent readings: Blood pressure changes between measurements can be missed, delaying recognition of hemodynamic instability.
• Inaccuracy under certain conditions: Movement, shivering, or poor peripheral circulation can affect cuff accuracy.
• Discomfort and skin trauma risks: Frequent cuff inflation may cause discomfort or skin bruising, particularly in sensitive or edematous tissues.
• Invasive arterial monitoring: While invasive arterial lines provide continuous and precise readings, they carry risks of bleeding, infection, thrombosis, and require specialized expertise, making them less practical for routine obstetric use.

The ClearSight System: An Overview

The ClearSight system by Edwards Lifesciences is an innovative, non-invasive technology that provides continuous beat-to-beat blood pressure measurement derived from volumetric clamping of the digital arteries (finger cuff method). Using a specialized inflatable cuff placed on the finger, the system monitors blood volume changes with a combination of infrared light and pressure sensors, allowing high-fidelity arterial pressure waveform acquisition without penetrating the skin.

Key Features:

• Continuous, real-time data: Allows instantaneous recognition of hemodynamic fluctuations.
• Accurate blood pressure waveform: Provides systolic, diastolic, and mean arterial pressure continuously.
• Derived hemodynamic parameters: Stroke volume, cardiac output, systemic vascular resistance, and stroke volume variation can be calculated to guide fluid and vasoactive drug therapy.
• Non-invasive and comfortable: The finger cuff design is lightweight and does not restrict patient mobility.
• Automated calibration: The system calibrates against brachial cuff pressures for accuracy.

Clinical Application in Pregnant Women at High Risk of PPH

In women at high risk of postpartum hemorrhage, the ClearSight system allows continuous monitoring from labor onset through delivery and immediate postpartum periods. This provides several clinical advantages:

Early Detection of Hemodynamic Instability

Subtle, progressive drops in blood pressure may precede overt clinical signs of hemorrhage. Continuous monitoring enables early identification of hypotension, allowing rapid intervention before severe hypovolemia or shock develop.

Guiding Fluid and Medication Management

By assessing hemodynamic parameters like stroke volume and cardiac output, clinicians can tailor fluid resuscitation and vasoactive medication administration. This targeted approach optimizes maternal cardiovascular stability and may reduce unnecessary fluid overload.

Reducing Need for Invasive Monitoring

The ClearSight system can diminish reliance on arterial catheterization, lowering associated complications and increasing patient comfort. This is particularly beneficial in obstetric patients who may have challenging vascular access and higher risk of bleeding abnormalities.

Improving Maternal and Neonatal Outcomes

By facilitating timely recognition and treatment of hemodynamic compromise, the system contributes to reduced rates of severe hemorrhage complications, including multi-organ failure and intensive care admissions, thereby improving overall maternal safety and potentially benefiting neonatal well-being through stable uteroplacental perfusion.

Supporting Evidence and Studies

Several clinical studies and case reports underscore the utility of ClearSight monitoring in obstetrics. For example:

• A prospective observational study in high-risk parturients demonstrated that ClearSight accurately tracked blood pressure trends during cesarean delivery under spinal anesthesia, detecting early hypotensive episodes before intermittent cuff measurements.
• Case reports have shown successful use in women with placenta accreta spectrum disorders, where rapid blood loss risk is significant and hemodynamic monitoring is essential for prompt transfusion and vasopressor support.
• Comparisons with invasive arterial lines have revealed good agreement in blood pressure readings, validating the devices accuracy in the obstetric surgical setting.

Practical Considerations in Implementing ClearSight Monitoring

Although promising, there are some practical aspects to consider for ClearSight use in pregnant women:

• Patient selection: While generally safe, patients with severe peripheral vascular disease or cold extremities may have less reliable signals.
• Proper positioning: Ensuring the finger cuff is at heart level is essential for accurate pressure measurement.
• Equipment availability and cost: As a specialized device, ClearSight may represent a higher upfront investment compared to standard non-invasive cuffs.
• Staff training: Clinicians and nursing staff should be familiarized with device setup, troubleshooting, and interpretation of hemodynamic data.

Future Directions

Continued research is needed to further define the role of non-invasive continuous blood pressure monitoring in obstetric care, particularly in relation to long-term maternal outcomes, cost-effectiveness, and integration with multimodal monitoring systems. Combining ClearSight data with other vital signs and clinical parameters may enable more sophisticated prediction models for PPH and personalized management algorithms.

Innovation in wearable sensors and wireless monitoring technology also holds promise for improving maternal monitoring beyond the labor and delivery suite, potentially supporting ambulatory surveillance in high-risk pregnancies.

Conclusion

Non-invasive continuous blood pressure monitoring using the ClearSight system represents an important advancement in managing pregnant women at high risk of postpartum hemorrhage. Its ability to provide continuous, accurate hemodynamic data enhances early detection of blood loss, guides individualized treatment, and reduces dependency on invasive methods. Integration of such technologies into obstetric practice has the potential to improve maternal safety, optimize resource use, and ultimately reduce the burden of PPH worldwide.

```